LifEscozul™ - Resultado paciente José Centeno

Results obtained in the LifEscozul Protocol in patient José Centeno.

In this interview, for the LifEscozul Protocol (Escozul, blue scorpion venom, blue scorpion) we spoke with José Centeno.

Mr. José Centeno entered the LIfEscozul Protocol in 2017. José was diagnosed with acinar adenocarcinoma of the prostate with possible metastasis in the pelvis.

During the first 5 months of treatment with LIfEscozul, José presented a continuous decrease in prostate antigen values 5 months after starting treatment:


  • - 116      October 2017
  • - 76.6    December 2017
  • - 38.3    January 2018
  • - 21.3     April 2018

This interview was conducted by Biologist Ariel Portal for the Protocol LifEscozul (Escozul, blue scorpion venom, blue scorpion venom).

José was treated with LifEscozul (protein active ingredient) with periodic controls and progressive dose increases.

For any questions please write to or fill out the form.

The LifEscozul Group™ continues with this interview a cycle of interviews with our oldest patients within the LifEscozul Protocol™ (Escozul™, blue scorpion venom, blue scorpion).

LifEscozul is a product with a registered trademark in the USA and Ecuador and in the process of registration in more than 20 countries. It has been developed by Cuban doctors and scientists based on the antitumor active ingredient extracted from blue scorpion venom (Escozul).

You may be interested in...